Regents of The University of California maintained its stake in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 27,645 shares of the biopharmaceutical company’s stock at the end of the second quarter. Pfizer comprises approximately 4.1% of Regents of The University of California’s holdings, making the stock its 8th biggest position. Regents of The University of California’s holdings in Pfizer were worth $929,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Shine Investment Advisory Services Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth $102,000. Mckinley Capital Management LLC Delaware acquired a new position in shares of Pfizer during the 2nd quarter worth $103,000. D. Scott Neal Inc. raised its holdings in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares in the last quarter. Herndon Capital Management LLC acquired a new position in shares of Pfizer during the 2nd quarter worth $120,000. Finally, Franklin Parlapiano Turner & Welch LLC acquired a new position in shares of Pfizer during the 1st quarter worth $121,000. 69.89% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts recently weighed in on the company. Deutsche Bank set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Barclays set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price objective on Pfizer and gave the stock a “buy” rating in a research report on Tuesday, October 10th. Finally, Jefferies Group set a $38.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Monday, October 16th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $38.77.

Pfizer Inc. (NYSE PFE) traded up $0.68 during midday trading on Friday, hitting $37.14. The company’s stock had a trading volume of 12,524,254 shares, compared to its average volume of 19,888,109. Pfizer Inc. has a 1 year low of $30.90 and a 1 year high of $36.89. The company has a market cap of $218,400.30, a price-to-earnings ratio of 14.66, a PEG ratio of 2.59 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The firm had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter in the previous year, the company posted $0.61 EPS. The business’s revenue was up .9% on a year-over-year basis. analysts forecast that Pfizer Inc. will post 2.59 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, December 1st. Shareholders of record on Friday, November 10th were given a $0.32 dividend. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.45%. Pfizer’s dividend payout ratio (DPR) is presently 79.01%.

In other Pfizer news, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the sale, the executive vice president now owns 117,432 shares in the company, valued at approximately $4,186,450.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/15/regents-of-the-university-of-california-holds-holdings-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related stocks with our FREE daily email newsletter.